

CAREFIRST
Antidiabetic Agents Step Therapy

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 800-294-5979 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Antidiabetic Agents Step Therapy .

Patient Information

Patient Name:	
Patient Phone:	
Patient ID:	
Patient Group:	
Patient DOB:	

Physician Information

Physician Name	
Physician Phone:	
Physician Fax:	
Physician Addr.:	
City, St, Zip:	

Drug Name (specify drug)

Quantity:	Frequency:	Strength:
Route of Administration:	Expected Length of Therapy:	
Diagnosis:	ICD Code:	
Comments:		

Please check the appropriate answer for each applicable question.

- | | | | | | |
|-----|--|---|--------------------------|---|--------------------------|
| 1. | Does the patient have a diagnosis of type 2 diabetes mellitus? | Y | ☐ | N | ☐ |
| 2. | Has the patient been receiving a stable maintenance dose of the requested drug for at least 3 months? | Y | ☐ | N | ☐ |
| 3. | Has the patient demonstrated a reduction in A1C since starting this therapy? | Y | ☐ | N | ☐ |
| 4. | Is this request for SymlinPen (pramlintide acetate)? | Y | ☐ | N | ☐ |
| 5. | Has the patient experienced an inadequate treatment response, intolerance, or does the patient have a contraindication to metformin? | Y | ☐ | N | ☐ |
| 6. | Does the patient require combination therapy AND have an A1C of 7.5 percent or greater? | Y | ☐ | N | ☐ |
| 7. | Which drug is being requested? [Please check the drug being requested (applies to brand or generic unless otherwise noted).] | | | | |
| | Farxiga (dapagliflozin) (If checked, go to 8) | | ☐ | | |
| | Invokana (canagliflozin) (If checked, go to 11) | | ☐ | | |
| | Jardiance (empagliflozin) (If checked, go to 13) | | ☐ | | |
| | Other (If checked, no further questions) | | ☐ | | |
| 8. | Does the patient have established cardiovascular disease or multiple cardiovascular risk factors? | Y | ☐ | N | ☐ |
| 9. | Does the patient have a diagnosis of heart failure? | Y | ☐ | N | ☐ |
| 10. | Does the patient have a diagnosis of chronic kidney disease at risk of progression? | Y | ☐ | N | ☐ |

- | | | | | | |
|-----|--|---|--------------------------|---|--------------------------|
| 11. | Does the patient have established cardiovascular disease? | Y | ☐ | N | ☐ |
| 12. | Does the patient have a diagnosis of diabetic nephropathy with albuminuria greater than 300 mg/day? | Y | ☐ | N | ☐ |
| 13. | Does the patient have established cardiovascular disease? | Y | ☐ | N | ☐ |
| 14. | Does the patient have a diagnosis of heart failure? | Y | ☐ | N | ☐ |
| 15. | Does the patient have a diagnosis of chronic kidney disease at risk of progression? | Y | ☐ | N | ☐ |
| 16. | Which drug is being requested? [Please check the drug being requested (applies to brand or generic unless otherwise noted).] | | | | |
| | SymlinPen (pramlintide acetate) (If checked, go to 17) | | ☐ | | |
| | Farxiga (dapagliflozin) (If checked, go to 21) | | ☐ | | |
| | Jardiance (empagliflozin) (If checked, go to 23) | | ☐ | | |
| | Other (If checked, no further questions) | | ☐ | | |
| 17. | Does the patient have a diagnosis of type 1 diabetes mellitus? | Y | ☐ | N | ☐ |
| 18. | Has the patient been receiving a stable maintenance dose of the requested drug for at least 3 months? | Y | ☐ | N | ☐ |
| 19. | Has the patient demonstrated a reduction in A1C since starting this therapy? | Y | ☐ | N | ☐ |
| 20. | Has the patient failed to achieve desired glucose control despite receiving optimal insulin therapy, including mealtime insulin? | Y | ☐ | N | ☐ |
| 21. | Does the patient have a diagnosis of heart failure? | Y | ☐ | N | ☐ |
| 22. | Does the patient have chronic kidney disease at risk of progression? | Y | ☐ | N | ☐ |
| 23. | Does the patient have a diagnosis of heart failure? | Y | ☐ | N | ☐ |
| 24. | Does the patient have chronic kidney disease at risk of progression? | Y | ☐ | N | ☐ |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.